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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2015, TaiwanAbstract Vascular dementia (VaD) affects a broad spectrum of patients with various manifes-
tations of cognitive decline, which could be attributed to cerebrovascular or cardiovascular
disease. Diagnosis of VaD depends on the identification of environmental and genetic risk fac-
tors including; cerebral autosomal-dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy. Mitochondrial oxidative stress, hypoxic ischemia, inflammation,
accumulation of advanced glycation products, and proinflammatory cytokines have been impli-
cated in the pathogenesis of VaD. Hence it is exceedingly important to determine the risk fac-
tors and molecular pathology by identifying specific biomarkers that can be broadly classified
as: biochemical, molecular, genetic, endocrinological, anatomical, imaging, and neuropatho-
logical; for the early differential diagnosis, prognosis, and effective treatment of VaD. The bio-
markers of VaD in the serum and cerebrospinal fluid samples include; phosphorylated tau,
amyloid-b, matrix metalloproteases, sulfatids, albumin, and proinflammatory C-reactive pro-
teins. In addition, Charnoly body (CB) formation and microRNAs can be detected as preapop-
totic biomarkers of compromised mitochondrial bioenergetics to further confirm VaD. CB
formation occurs in response to nutritional stress and/or neurotoxic insult in the most vulner-
able hippocampal neurons due to cerebrovascular insufficiency, and can be attenuated by di-
etary interventions, physiological zinc supplementation, and metallothioneins (MTs). MTs
provide ubiquinone-mediated neuroprotection by serving as free radical scavengers, by main-
taining the mitochondrial redox balance, by inhibiting CB formation, and by inhibiting progres-
sive neurodegenerative a-synucleinopathies. MTs also regulate zinc-mediated transcriptional
activation of genes involved in cell growth, proliferation, and differentiation, and hence
may be used as novel biomarkers of VaD. In addition to genetic analysis of MTs, Notch3, apoli-
poprotein E4, nitric oxide synthase, and cerebral autosomal-dominant arteriopathy with
subcortical infarcts and leukoencephalopathy; omics and microRNA analyses may provide novel
biomarkers of VaD. This review provides recent update on in-vitro biomarkers from the serumSchool of Medicine, Plaza Juliana 4, Kralnedijk, Bonaire, Dutch Caribbean, The Netherlands.
.org (S. Sharma).
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44 A. Jagtap et al.and cerebrospinal fluid samples and in-vivo neuroimaging biomarkers for the differential diag-
nosis and effective clinical management of VaD.
Copyright ª 2015, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
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Dementia may be defined as a progressive neurodegenera-
tive disease characterized by loss of cognition, significant
enough to cause functional disability in everyday life.1,2 It
is a major public health problem affecting over 20 million
people around the world and the number is increasing
exponentially in industrially-developed countries.3 The
prevalence of two major types of dementia, Alzheimer’s
disease (AD) and vascular dementia (VaD), is around 4.4%
and 1e2 % respectively in industrially-developed countries;
however, the prevalence is lower in developing countries.4
AD accounts for 70e75% cases of dementia in elderly,
whereas VaD comprises a small but significant group ac-
counting to around 20% cases, the second most common
form of dementia after AD.4,5 Vascular comorbidity may be
present in over 30% patients with AD and over 50% patients
with VaD may exhibit pathology associated with AD, sug-
gesting a 3.4e73% overlap between AD and VaD.6 Hence,
the diagnosis of dementia is not only difficult but also
challenging as in many elderly patients both the entities
may coexist in combination with other neurodegenerative
diseases (often termed as mixed dementia). The original
term multi-infarct dementia is now replaced by a newly
updated term, vascular cognitive impairment (VCI), which
refers to any cognitive impairment caused by or associated
with vascular risk factors and ranges from mild cognitive
impairment to overt dementia.7 VaD may be caused by
hemorrhagic, ischemic, and hypoxic injury to the brain. It is
a group of heterogeneous disorders in which the presence
of ischemia/infarction may cause cognitive decline how-
ever, the degree of such impairment is directly proportional
to the extent of neuronal damage and location of the
lesion.2,8e10 The National Institute of Neurological Disor-
ders and Stroke and Association internationale pour la
Recherche et l‘Enseignement en Neurosciences (NINDS-
AIREN) states that small vessel disease such as microvas-
cular angiopathy (lacunar infarction), periventricular
ischemia, and large vessel athero-embolic disease causing
territorial infarction are sufficient to result in cognitive
impairment and can be included as a criterion of VaD
diagnosis.1,2,11 Several possible pathogenic factors, such as
accumulation of advanced glycation end-products and
activation of proinflammatory cytokines [interleukin (IL)-
1b, tumor necrosis factor (TNF)a, IL-6, and nuclear factor-
kB], and experimental studies on animals and cultured
neurons have demonstrated that oxidative stress, mito-
chondrial dysfunction, inflammatory response and accu-
mulation of abnormal amyloid-b have been proposed for
the etiopathogenesis of VaD.4 As per California criteria,
diagnosis of VaD requires neuropathological assessment,
computed tomography (CT), positron emission tomography(PET), magnetic resonance imaging (MRI), and magnetic
resonance spectroscopy (MRS).2,12e14 Fig. 1 is a systematic
diagram illustrating various factors involved in the patho-
genesis and risk factors of VaD. In principle, the risk factors
for stroke are also the risk factors for dementia. Clinically-
evident hypertension has been shown to have significant
association with dementia while hyperlipidemia and
metabolic syndrome could be predictive of dementia
risk.2,15e17 Transient ischemic attacks also predispose to
increase the risk of stroke and 30% of the patients who
suffer stroke develop dementia after a period of 6e12
months. Although the exact etiopathogenesis of VaD re-
mains unknown, diabetes mellitus, hormone replacement
therapy for postmenopausal women, obesity, improper di-
etary habits including: food rich in trans-saturated fats and
lacking omega-3 fatty acids (docohexanoic acid and eico-
sapentanoic acid) and polyunsaturated fatty acids (linoeic
acid, linolinic acid, and arachidonic acid), various envi-
ronmental neurotoxins; drug addiction; aging; and un-
healthy life style including sedentary life style, lack of
exercise, physical and mental stress, overmedication, and
late night sleep have been proposed in the etiopatho-
genesis of VaD and can enhance the disease process.
Several of these risk factors, apart from genetic, may be
prevented by diet manipulation, moderate exercise, and
lifestyle modifications. Age of onset of stroke and lack of
education have also been associated with higher risk of
dementia.2 Cerebral autosomal-dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL), an
inherited disorder, manifested as syndrome of migraine,
mood disorder, recurrent transient ischemic attacks,
stroke, and early development of dementia is an indepen-
dent age-related pathogenesis of AD and VaD; the root
cause is primarily microvascular disease. Due to the
numerous attributable risk factors detailed studies are
needed to understand the exact etiopathogenesis of VaD.
In the present report, we describe systematically recent
updates on various in-vitro biomarkers from serum and
cerebrospinal fluid (CSF) samples and in-vivo multimodality
neuroimaging biomarkers for the effective clinical man-
agement of VaD. It is expected that the information in this
review will be of significant interest to medical students,
clinicians, and researchers interested in understanding
further about this devastating progressive neurodegenera-
tive disorder of unknown etiopathogenesis.
Classification of biomarkers in VaD
Accurate classification of dementia would significantly
impact its treatment. Currently, there is no approved drug
for the treatment of VaD, so it is exceedingly important to
reduce the risk factors and provide adequate treatment
Figure 1 Risk factors and pathogenesis of vascular dementia (VaD). A pictorial diagram illuatrating various risk factors including
hypertension, hyperlipidemia, obesity, drugs of abuse, overmedication, hormone replacement therapy, and environmental factors
could lead to the pathogenesis of VaD. Activation of proinflammatory cytokines, abnormal accumulation of amyloid-b, accumu-
lation of advanced glycation products, inflammation, and mitochondrial oxidative stress are caused by hypoxia, hemorrhage, and
ischemia, resulting in the pathogenesis of VaD.
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longing the onset of dementia. The major risk factors, hy-
pertension, and hyperlipidemia, can be controlled only
with conventional treatment to reduce the risk of VaD.
Therefore there is a dire need to classify and determine the
specific etiology of dementia based on the biomarkers an-
alyses. These biomarkers must be easily measurable to
facilitate early and accurate diagnosis. In this regard, the
surrogate biomarkers of VaD, based on functional neuro-
imaging, and CSF- and blood-based analysis have gainedimportance as these are noninvasive or minimally invasive,
easy to perform as compared to pathological analysis on
postmortem brain samples. Moreover, premortem analysis
of these biomarkers would enhance the diagnostic capa-
bility of VaD.18 The most significant VaD biomarkers that
could be used for the early clinical diagnosis, prognosis, and
treatment of VaD are presented in Fig. 2. These can be
broadly classified as: clinical biomarkers (neurobehavioral
assessment); pathological biomarkers (identifying cellular/
histological changes); biochemical biomarkers (serum,
46 A. Jagtap et al.plasma, CSF biomarkers); neuroimaging biomarkers, which
include functional multimodality fusion imaging with CT,
MRI/MRS, PET, and single photon emission CT (SPECT) to
derive structural as well as functional information simul-
taneously regarding the diseases process, genetic bio-
markers (identifying genes involved in cerbrovascular
disease); and omics and microRNA biomarkers (identifying
subcellular components of VaD). Simonsen et al recently
described laboratory methods for collection, detection of
proteins in CSF and plasma along with purification of
candidate biomarkers (chromatographic and electropho-
resis technique) and protein profiling using multiplex
enzyme-linked immunosorbent assay, surface enhanced
laser desorption/ionization time of flight mass spectrom-
etry, and peptide mass fingerprinting.5 Various statistical
methods to calculate probability, sensitivity, and specificity
have been described to determine the utility of these bio-
markers. Although several biomarkers have been correlated
with underlying pathological processes at the cellular and
molecular level; the biochemical biomarkers have been
directly correlated with clinical and imaging findings in
dementia. However, their pathological correlation is yet to
be established.19,20 Humpel reported that the detection of
biomarkers in CSF can only support the clinical diagnosis of
VaD.21 Recent studies on biomarkers have emphasized on
inflammation, hemostasis, oxidative stress, hypo-
xiaeischemia, accumulation of biochemical substances,
complex proteins, and other metabolites in the hyper-
tensiveeatheromatous disease and hyperlipidemia in tissue
and CSF.4,22Figure 2 Classification of vascular dementia (VaD) bio-
markers. A diagram demonstrating various biomarkers in VaD
such as: omics/microRNA, genetic biomarkers, neuroimaging
biomarkers, cerebrospinal fluid (CSF) and serum biochemical
biomarkers, pathological biomarkers, and clinical biomarkers,
which can be used for the differential diagnosis, prognosis, and
effective treatment of VaD.CSF biomarkers of VaD
Although biomarkers can be measured in various body fluids
such as saliva, blood, and urine and tissue, CSF has been
studied extensively because it drains the ventricular system
of the brain and concentration of various metabolites may
directly reflect various pathological processes in the brain
providing a lead to develop sensitive and specific biomarker
in CSF to differentially diagnose various etiological types of
dementia.21 CSF biomarkers in dementia have been re-
ported, especially in patients with AD on a larger scale and
have shown promise as sensitive diagnostic tool; however,
very few studies are yet available and the candidate CSF
biomarkers studied so far show conflicting results and lack
specificity due to the heterogenous nature of VaD. As Table
1 summarizes, the protein biomarkers that can be used
qualitatively and quantitatively; although they are not
specific to VaD when used in combination, they can in-
crease the diagnostic certainty of VaD. CSF serum albumin
ratio, CSF index, and CSF total protein are biomarkers
having high diagnostic value as these can identify structural
and functional integrity of the bloodebrain barrier and
microvascular damage. An increased albumin level and
increased index in VaD patients are well established, but
they are nonspecific and may not distinguish VaD from
AD.23,24 Sulfatide a maker for demyelination, is used to
identify the extent of demyelination in the white matter
and it is found to be elevated in VaD as reported by Tullberg
et al25 and Fredman et al.26 The cytoskeletal organelle,
neurofilament is estimated to identify axonal degeneration
and the extent of white matter damage, and is found to be
increased in CSF of patients with VaD but not with AD pa-
thology, reflecting the axonal damage that is characteristic
of VaD.24,27 Furthermore, the matrix metalloproteases
(MMPs) in the CSF, can be estimated to identify changes in
the extracellular matrix associated with vascular diseases
with inflammation.28 MMPs attack the myelin and are
regarded as biomarkers of demyelination. Various studies
including autopsy studies have shown that MMPs are
increased in patients with VaD.29,30 Certain CSF biomarkers
were used earlier for the evaluation of diagnostic utility in
AD. Conflicting results in multiple studies have been re-
ported and their potential utility lies in differentiating VaD
from AD and the other neurodegenerative diseases. How-
ever, many studies show significant overlap between levels
in VaD and AD.5,6 Serum to CSF folate ratio can be used to
differentiate VaD from AD. This ratio is significantly
reduced in VaD. The reduced folate ratio has been found to
be a characteristic of VaD.5,31 In addition AD is character-
ized by amyloid (A)b plaque deposition irrespective of its
etiopathogenesis. Amyloid-b peptide (1e42) (Ab-42) is
formed after amyloid-b is cleaved from amyloid precursor
protein by secretases. A significant reduction of Ab-42 in
patients with AD as well as VaD suggests a significant
overlap making it difficult to distinguish AD from VaD.5,6 Ab-
42, total tau and phosphorylated tau (p-tau) have been
extensively studied in AD and there are several reports on
their utility in diagnosis and prognosis of AD. Increased
levels of tau and decreased levels of Ab-42 have been
detected in AD as well as VaD but more specifically in AD.
Hence a combined analysis of these CSF biomarkers has
Table 1 Cerebrospinal fluid (CSF) biomarkers with high diagnostic utility: (Biomarker levels in CSF are raised in vascular
dementia, VaD).
Biomarkers Diagnostic utility
CSF:serum albumin ratio,
CSF total protein
To identify bloodebrain barrier damage to the small intravascular vessels
Sulfatide To identify demyelination of white matter
Neurofilament To identify axonal degeneration (marker of white matter damage)
Matrix metalloproteases To identify changes in the extracellular matrix associated with cardiovascular disease (i.e.
vascular disease with inflammation)
Serum to CSF Folate ratio Low ratio in VaD
Increased total tau, p-tau,
decreased amyloid b42
May differentiate VaD from Alzheimer’s disease and other NDD
(Neurodegenerative Diseases)
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VaD.20,32e35 The protein biomarkers as mentioned in Fig. 3
represent various physiological processes such as protein
degradation (ubiquitin), protease inhibition (cystatin C and
a1 anti-chymotrypsin), inflammation (C3a, C4a) are known
to be associated with neurodegenerative diseases including
all forms of dementia. However, their diagnostic utility is
enhanced when used in combination with folate ratio, Ab-
42, total tau, or p-tau levels. Simonsen et al conducted the
first study to establish the status of these candidate bio-
markers in VaD patients.5 These markers lack specificity
and need to be validated and investigated in large pro-
spective multicentric trials. A biomarker of neuronal death,
heart fatty acid binding protein is elevated in CSF from
patients with various neurodegenerative diseases. Although
heart fatty acid binding protein can be detected in early
VaD and AD, it lacks specificity.36
Serum and plasma biomarkers of VaD
Apart from CSF, certain biomarkers have been identified in
the serum and plasma from the blood samples of patients
with VaD, AD, and other neurodegenerative diseases. C-
reactive protein is an inflammatory biomarker and its levels
are elevated in VaD. Hyperhomocysteinemia is a well-
established vascular risk factor and increased level of
serum homocysteine proves a causal relationship with
vascular lesions and thereby VaD.37,38 Elevated levels of
serum homocysteine were also seen in AD patients and are
considered to contribute to vascular pathogenesis of AD.
Recently, many studies have shown that elevated serum
homocysteine is associated with hippocampal and cortical
atrophy in patients with VaD.39 Although deficiency of
vitamin B12 and folate causes hyperhomocysteinemia, the
supplementation of these vitamins failed to produce any
improvement in patients with dementia; hence role of ho-
mocysteine remains controversial.40 Elevated lipoprotein-a
is considered an independent genetic risk factor for VaD but
not in AD, which helps in understanding the pathogenesis of
atherogenic processes in VaD.41,42 Dehydroepiandrosterone
(DHEA), a neurosteroid, and its metabolite, DHEA sulfate
(DHEA-S) have neuroprotective effects and their levels in
the central nervous system are raised in neurodegenerative
diseases however, the reason for their altered levels in
blood as a cause or as an effect remains uncertain.43e45
Serum level of DHEA-S is unaltered as reported by a fewstudies in patients with VaD. A detailed study is needed to
determine the exact clinical significance of these and other
biomarkers in the differential diagnosis of VaD, as several
factors may influence their levels in blood. Furthermore,
these biomarker studies should be correlated and
confirmed with imaging and histopathological evidence to
authenticate VaD diagnosis. Similarly oxidative stressors
such as malondialdehyde (MDA), thyroid stimulating hor-
mone (TSH), calcium, and magnesium have been found to
be nonspecifically elevated in patients with dementia,
suggesting vascular etiopathogenesis in dementing ill-
nesses.46 The receptor for advanced glycation end products
(RAGE) is a cell-bound receptor of the immunoglobulin su-
perfamily that may be activated by proinflammatory li-
gands including advanced glycol-oxidation end products
and amyloid-b peptide. Clinical studies have shown that
higher plasma levels of RAGE are associated with reduced
risk of coronary artery disease, hypertension, metabolic
syndrome, arthritis, and AD.47 Similarly, atherosclerotic
cerebrovascular disease is a significant cause of VaD. So,
the protective nature of this biomarker requires further
validation. Geroldi et al recently demonstrated that only
RAGE and b-site amyloid precursor protein (APP) cleaving
enzyme 1 (BACE-1) proved to be predictor of cognitive
impairment after stroke but there was no association with
neprilysin or apolipoprotein E (ApoE).48 It needs to be
determined whether these biomarkers help in distinguish-
ing VaD from vascular cognitive impairment after acute
ischemic stroke. Increased levels of thrombin, D-dimer, and
thrombin fragment 1þ2, and biomarkers of endothelial
dysfunction (von Willebrand factor and plasminogen acti-
vator inhibitor) are associated with cerebrovascular
thrombosis and thereby VaD as illustrated in Fig. 4. Such
association may be secondary to chronic inflammation.
These mechanisms may underlie prothrombotic state, ce-
rebral microinfarction, and eventually subcortical small
vessel infarction. Most of the cases of dementia have mixed
etiopathogenesis, contributing a variable amount of
vascular pathology (Neuropathology group of the Medical
Research Council Cognitive Function and Ageing Study).49,50
Genetic biomarkers of VaD
Identifying new risk factors for ischemic stroke could help
improve prevention strategies and identify new therapeutic
targets. Genetic risk factors are particularly interesting,
48 A. Jagtap et al.because they can offer a direct clue to the biological
pathways involved. Ischemic stroke is a heterogeneous
disorder, and must be considered for genetic susceptibility
factors. In Western countries, most ischemic strokes can be
attributed to large-artery atherosclerosis (athero-
thrombotic stroke) and small-artery occlusion (lacunar
stroke).51 The genes underlying VCI must be of two exclu-
sive classes: (1) genes that predispose individuals to cere-
brovascular disease, and (2) genes that determine tissue
responses to cerebrovascular disease (e.g. genes conveying
ischemic tolerance or susceptibility, or the ability to
recover from ischemic insult).52 In the first category, genes
that confer susceptibility to hypertension and atheroscle-
rosis have been identified with some monogenic forms of
disease such as CADASIL caused by mutations in NOTCH 3
gene. From the second category; genes that modify tissue
responses to injury have also been identified and at least
three sets of genes in the AD pathway, the presenilins, APP,
and APOE are known to interact with the VCI disease
pathway. The presenilin mutations causing AD have been
shown to interact directly with Notch proteins, including
Notch 3 (mutations of which cause CADASIL).53e55 There is
direct evidence from both human and animal studies for
specific non-AD genes that play a significant role in tissue
responses in ischemia. Earlier studies in humans suggest
that variants in the genes for platelet glycoprotein and a-
fibrinogen affect post stroke outcomes without affecting
stroke risk per se. Animal studies have suggested glutamateFigure 3 Cerebrospinal fluid (CSF) protein biomarkers mainly use
that are altered in vascular dementia (VaD) and Alzheimer’s disea
Apolipoprotein-A1, dimers of apolipoprotein-A2, albumin, and im
compared to AD patients, whereas integral membrane 2BeC, termin
C, ubiquitin-3a from computed tomography, neuroendocrine prote
lower in VaD as compared to AD patients.and g-aminobutyric acid receptors, acid-sensing ion chan-
nels, proteases, growth factors and their receptors, and
transcription factors as the major molecules involved in
influencing brain responses to cerebrovascular injury.56,57
In addition, chromosome 9p21.3 genotype has been asso-
ciated with VaD and AD.58 Linkage and association analyses
(including single nucleotide polymorphism EDN1, MHTFR,
NOS3, and ApoE 4) and AGTR1, AGTR2 of renal angiotensin
system) have shown the association of these genes with
pathogenesis of small vessel disease, cardiovascular disease
(CVD), and VaD. The genes/molecules described in Fig. 5
have been studied extensively in relation to CVD and at-
tempts are being made to determine predisposition to CVD
and VaD.51,59 Genetic diseases such as sickle cell disease,
Fabry disease, and homocysteinuria, and genes involved in
inflammation (LTC4S, IL-6), thrombosis (TGB3, factor VIII),
lipid metabolism (ApoE, PON 1 PON2, PON3, ApoA5, LPL,
LDL), endothelial function and oxidative stress (NOS3,
MTHFR) and genes identified through linkage analysis in an
Icelandic population (ALOX5, PDE4d) are all candidate
biomarkers to establish association with cerebrovascular
disease, ischemia-stroke, and VaD.51 There are limited
studies available regarding the genetic biomarkers in VaD
(Fig. 6). Hence potential genetic and molecular biomarkers
of VaD such as genes responsible for cerebrovascular dis-
ease, genes influencing the native tissue response and
molecules such as soluble receptors for various metabolites
and enzymes identified in VaD, have been proposed asd in combination. A pictorial representation of CSF biomarkers
se (AD). These biomarkers possess moderate diagnostic utility.
munoglobulin-G have higher levels in the CSF samples of VaD
al fragment, C3a peptide lacking c-terminal arginine, cystatin-
in 7B2 (secretogranin V), and C4a peptide des-Arg levels are
Figure 4 Candidate vascular dementia (VaD) biomarkers in plasma/serum. C-reactive protein, homocysteine, lipoprotein-A,
malondialdehyde, total eSH, calcium, magnesium, thyroid stimulating hormone (TSH) b-secratase, neprilysin levels are
increased in VaD as compared to normal control and AD patients. DHEA-S levels remain unaltered in VaD but are reduced in AD
patients. Folate and vitamin B12 and s-RAGE are lowered in VaD as compared to AD patients.
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VaD. However, further studies are needed to establish their
clinical significance.47,60 The proposed biomarker genes
predisposing to cerebrovascular disease are ACE, AGT,
eNOS, PON, MTHFR, MEF2A, ALOX5, LTA, APOM, and PDE4D.
Certain genes can influence the brain tissue response to
VaD such as neurotrophic factors: brain-derived neuro-
trophic factor (BDNF), nerve growth factor (NGF), vascular
growth factors, ApoE, MMPs, glutamate, and GABA re-
ceptors, adhesion molecules, transcription factors, ion
channels, and NOS pathway genes. Genes/loci that are
known to alter risk of VaD in a community are PDE4D,
ALOX5AP, LTA4H, 9p21, 4q25, ApoE 4 in CADASIL, specific
pathway genes, APP, PPAR-g, LPL, and LIPC.51,59MicroRNA biomarkers in VaD
Various types of microRNAs (miRs) are impaired due to
abnormal adipogenesis in obesity to influence the genetic
predisposition of VaD. A further study is required to
determine their exact significance in the clinical manage-
ment of VaD. Further studies employing omicsbiotechnology and miR analysis would provide precise
knowledge regarding the exact etiopathogenesis and clin-
ical management of VaD in future. Early mild cognitive
impairment syndrome in vitro can be estimated by quan-
titative analysis of brain-enriched cell-free miR in the blood
using quantitative real-time polymerase chain reaction. As
miRs are important epigenetic regulators of numerous
cellular processes including neurodegenerative diseases,
specific miRs such as the miR-132 and miR-134 families
paired with miR-491-5p and miR-370, respectively, have
proven to be the best, detecting mild cognitive impairment
of varied etiology and AD. The use of brain-enriched neu-
rites/synapses miR enables detection of early pathologic
events occurring in degenerating neurons.61 Numerous miRs
including guardian of endothelial cells, miR 126 (lowered
level) and others are found in vascular inflammatory pro-
cesses, and could serve as biomarkers of early detection of
vascular cognitive impairment. Also, therapeutic potential
of miRs is a future challenge. The invention of novel mod-
ifications of RNA bases and the synthesis of artificial anti-
sense miR or antagomir, may be used as novel therapeutic
tools to manipulate miR and control vascular inflammatory
diseases.62 Although free radicals can induce inflammation
Figure 5 Molecular biomarkers in vascular dementia (VaD). A pictorial diagram illustrating genes such as ACE, AGT, eNOS, PON,
MTHFR, MEF2A, ALOX5, LTA, APOM, and PDE4D are the genes predisposing to cerebrovascular disease. Genes which influence the
brain tissue responses include neurotropic factors brain-derived growth factor (BDNF), nerve growth factor (NGF), and vascular
endothelial-derived growth factor (VEGF), apolipoprotein-E (APOE), and matrix metalloproteinases, glutamate and GABA re-
ceptors, adhesion molecules, transcription factors, ion channels, NOS pathways genes. The genes known to alter risk of cere-
brovascular diseases in community are: PDE4D, ALOX-5AP, LTA4H, chromosome-9 p21, 4q25, APO-4 in CADASIL, and specific
pathway genes such as APP, PPAR-g, LPL, and LIPC.
50 A. Jagtap et al.by activating redox-sensitive proinflammatory transcription
factors, the endothelial dysfunction induced by oxidative
stress can release vascular endothelial-derived growth
factors (VEGFs) and prostanoids promoting vascular
leakage, protein extravasation, and cytokine production.
Inflammation enhances oxidative stress by upregulating the
expression of reactive oxygen species-producing enzymes
and downregulating antioxidant defenses. miRs of these
transcription factors can act as potential biomarkers in
circulation for VaD. A study published by Ungvari et al,
suggests Dicer1 (ribonuclease III) is a key enzyme of the miR
machinery, which is responsible for synthesis of mature
functional miRs.63 There is evidence that Dicer1 in endo-
thelial cells may regulate angiogenic processes, a
biomarker to be explored as therapeutic target. Role of
dysregulation of Dicer1 in age-related impairment of
angiogenesis identified a number of miRs that are down-
regulated in cerebromicrovascular endothelial cells indementia. Aging results in cerebromicrovascular rarefac-
tion and cerebral angiogenesis is impaired in response to
hypoxia or VEGF administration. This plays a prominent role
in impairment of regional cerebral blood flow and the
occurrence of VCI with age. Because the role of miRNA
regulation and function in the aging vascular system is an
emerging area, further research is needed to study the
contribution of individual miRs or miR families in gene
expression that underlie microvascular aging and thereby,
VaD.Biomarkers of cell-based therapy for VaD
There are few studies as yet available on the therapeutic
potential of cell-based therapy in VaD. Laboratory studies
have shown that transplanted bone marrow stem cells
improve neurological diseases of the CNS by generating
Biomarkers in vascular dementia 51neural cells or myelin-producing oligodendroglial cells and
enhancing neural plasticity.64e68 However there are few
objective data providing evidence for clinical improve-
ment. Sharma et al administered autologous bone marrow
derived mononuclear cells, intrathecally to a 61-year-old
woman who was diagnosed with VaD.69 After follow-up of 2
years she showed clinical improvements as assessed by
mini-mental state examination and functional indepen-
dence measure along with PET/CT neuroimaging exhibiting
improved metabolic activity providing evidence of benefits
of cell-based therapy and suggestion to investigate various
stem cell biomarkers employing omics biotechnology in
future studies on VaD.
Recently, significant efforts have been made to explore
the basic molecular mechanisms of atherosclerosis (the
underlying cause of cerebrovascular and cardiovascular
disease), which remains a major cause of morbidity and
mortality worldwide. Because of the complex pathophysi-
ology of cardiovascular disease, different research methods
have been combined to unravel genetic aspects, molecular
pathways, and cellular functions involved in atherogenesis,
vascular inflammation, and dyslipidemia to gain a multi-
faceted picture addressing this complexity. Recent evolu-
tion of high-throughput technologies is able to generate
data at the DNA, RNA, and protein levels with sophisticated
computational technology. These data sets are integrated
to enhance information and are being used as regulated
networks. Doring et al described genomics, tran-
scriptomics, proteomics, and epigenomicsdand systems
biology to explore pathomechanisms of vascular inflam-
mation and atherosclerosis.70 Cerebrolysin, a naturallyFigure 6 Regulation of vascular dementia (VaD) biomarkers by
demonstrating various risk factors including altered circadian rhyt
lack of exercise can induce CB formation, and obesity due to abnor
leptin and orexin gene dysregulation. Omega-3 fatty and PUFA pre
and stabilization.occurring substance represents a therapeutic strategy for
neurological disorders like dementia, stroke, and traumatic
brain injury.71 It is a neuropeptide mimicking the action of
neurotrophic factors that enhances neurogenesis, sustain-
ing the brain’s self-repair, promotes neural progenitor cell
migration, synaptic density rebuilding neuronal cytoarchi-
tecture, restorative processes, decreases the infarct vol-
ume and edema formation and promotes functional
recovery. Since mitochondrial redox balance is impaired as
a consequence of brain regional cerebrovascular insuffi-
ciency, antioxidants such as quercetin and isoquercitrin as
natural flavonoids help to provide mitochondrial neuro-
protection in VaD. Similarly, melatonin reduces free radical
generation by enhancing glutathione levels. Neurotrophic
factors such as NGF, glial cell-derived neurotrophic factor,
and BDNF have already been implicated as targets for
treatment of degenerative diseases. These neurotropic
factors are generally present in significantly high amounts
in the bone marrow-derived mononuclear cells. A recom-
binant DNA vaccine composed of domains of neurite
outgrowth inhibitors. The immunological mechanism
inducing effective antibodies against the specific domains
and the modulation of mRNA expression regarding neurite
outgrowth inhibitors, which help in repair/regeneration of
neural and oligodendrocytic damage. Stem cells might be
an alternative to brain regeneration. In experimental
models of acute ischemic stroke using Q-dot labeled
mononuclear cells, we have established that these cells
exhibit preferential chemotaxis in the peri-infarcted region
and are exponentially eliminated as a function of time.
Although the exact molecular mechanism ofomega-3 and polyunsaturated fatty acid (PUFA). A diagram
hms, drug abuse, environmental and psychological stress, and
mal microRNA and abnormal adipogenesis as a consequence of
vent vascular dementia by providing new membrane synthesis
52 A. Jagtap et al.neuroprotection offered by mononuclear cells remains
enigmatic, it is assumed that the neuroprotection is pro-
vided by autocrine and paracrine mechanism by local
release of neuroprotective biomarkers such as insulin-like
growth factor, endothelial derived growth factor, von
Wilebrand factor, and granulocyte colony stimulating fac-
tor, IL-4, and IL-10 as anti-inflammatory cytokines. Naive
human chorionic villi and amniotic fluid derived cells
release significant amounts of BDNF, as well as VEGF.
Nimodipine, as an L-type voltage-dependent Ca2þ channel
antagonist and an antihypertensive agent, can also reduce
ischemic nerve cell death in VaD. Further studies in this
direction promise to discover sensitive and specific bio-
markers of VaD.
Neuroimaging biomarkers
Neuroimaging has been extensively studied in various types
of dementia including VaD. In particular, CT and MRI spe-
cific changes have been identified as potential biomarkers
demonstrating mechanisms of vascular injury and their ef-
fects in the parenchyma, which can be detected in all the
stages of VaD.1 Phase contrast MRI and the analyses of
hemodynamics in the brain have also been regarded as
potential biomarkers, although their sensitivity and speci-
ficity need considerable evaluation. Neuroimaging findings
correlate very well with the underlying pathological pro-
cesses and hence have gained importance in research and
clinical investigation on VaD.1,28 Significant findings on
standard and routine neuroimaging techniques that can be
utilized as biomarkers in the diagnosis of VaD are summa-
rized in Table 2. It has been proved that T2 weighted MRI
sequences alone or in combination with CT can identify
leukoaraiosis (white matter lesions), microvascular angi-
opathy, lacunar infarction, dilation of VirchoweRobin
spaces, pulse wave encephalopathy, parameters of cere-
bral embolic disease, which have been correlated withTable 2 Imaging biomarkers in vascular dementia (VaD).
Imaging method Biomarkersdsalient features in VaD
Magnetic resonance
imaging (T1,T2
weighted and FLAIR
images)
Deep white matter hyperintensity
Periventricular hyperintensity
Infarction (lacunar, site specific such
gangliaecystic lesions, number, and
High signals in basal ganglia
Dilated VirchoweRobin space
Pulse wave encephalopathy seen as
infarction and white matter hyperin
Hemorrhage (number, size and locat
Brain atrophy
Computed tomography
scan
Ventricular size, medial temporal at
acute or chronic hemorrhage, hypod
defining infarction as per size, locat
Transcaranial Doppler Spontaneous cerebral emboli
CVD Z cardiovascular disease.postmortem findings of vascular pathology of dementia.1
However, there is still a need for the development of im-
aging parameters having diagnostic utility but also having
capacity of determining etiopathogenesis, differentiating
VaD from AD and other neurodegenerative diseases. Ligand-
specific PET and SPECT will serve as future diagnostic
methods when these ligands are developed for different
proteins found in VaD e.g. Tau, Ab 40 and many others.
Arterial spin labeling, which measures absolute blood flow
though cerebral vessels may offer better results than SPECT
in detecting hypoperfused areas. Moreover it is cost
effective and avoids use of radioactive substances. Func-
tional MRI can assess neuronal function through blood ox-
ygen level-dependent changes. Although the neurovascular
mechanism underlying blood oxygen level-dependent
changes is still poorly understood, functional MRI is being
used in neurological research. T2-T2
0-T2 relaxometry and
susceptibility-weighted MRI takes into account not only the
magnitude but also the phase and signals for gradient echo
MRI sequence. Susceptibility-weighted MRI, which has
ability to differentiate calcium, iron and hemorrhagic
products, can be a promising biomarker in differentiating
the aging brain from VaD.72Pathological biomarkers of VaD
The definitive diagnosis of VaD depends on the histo-
pathological analysis of postmortem brain samples or an-
imal models, which not only confirm the specificity of
biomarkers but also facilitate classifying the disease pro-
cess at the cellular and molecular level. The character-
istic pathology such as microvascular angiopathy,
CADASIL, hypertensive vasculopathy, cerebral amyloid
angiopathy (CAA), and atheroembolic or thrombotic dis-
eases have been identified and well-documented.1,7,73Diagnostic utility
Strongly correlated with small vessel CVD,
embolic disease and VaD (Mills)
Associated with CVD, ischemic disease
as basal
size)
Strongly associated with CVD and VaD
Represents atherosclerotic arteries and VaD
Strongly related to VaD on autopsy studies.
lacunar
tensity
Related to abnormal pulse pressure and
Windkessel effect leading to CVD
ion) Associated with CVD
Estimates age related, site related changes and
vascular pathology
rophy,
ensities
ion
Data not validated. Association with VaD is not
yet proven.
Related to embolic infarct and VaD
Biomarkers in vascular dementia 53Various pathological VaD biomarkers are illustrated in
Table 3. Theses biomarkers can be divided into six major
categories: (1) biomarkers of CADASIL; (2) biomarkers of
microvessel angiopathy; (3) biomarkers of hypertensive
vasculopathy; (4) biomarkers of cerebral amyloid angiop-
athy; (5) biomarkers of atherosclerosis or thrombotic
disease; and (6) CB formation due to mitochondrial
degeneration and eventually apoptosis of the most
vulnerable cells in the hippocampal dentate gyrus and CA-
3 regions due to cerebrovascular insufficiency in
VaD.14,74e80
Clinical biomarkers in VaD
Clinical assessment of VaD is based on neurobehavioral
biomarkers that are assessed by performing mental status
examination (MSE). MSE evaluates the extent of intellec-
tual deterioration and personality change. This is followed
by language performance test to acquire high yield results
for the clinical assessment of VaD.81 Among the different
types of MSEs, Mini MSE of Folstein, Hachinski ischemic
score scale, and Wechsler adult intelligence scale have
been found to be most useful. These tests use evaluation of
attention span, temporal, and spatial orientation and
retentive (declarative) memory. A score < 23 on Mini MSE
of Folstein is usually diagnostic of dementia. Further typing
is based on identification of risk factors as in VaD.82,83Table 3 Neuropathological biomarkers.
Category Biomarkers
Biomarkers of CADASIL
(Cerebral autosomal
dominant arteriopathy with
subcortical infarcts and
leukoencephalopathy)
CADASIL, CRV, HERNS
Biomarkers of microvascular
angiopathy
Thickening of small vessel wall,
narrowing, degeneration of tun
fibrinoid necrosis, inflammation
Vasculitides
Biomarkers of hypertensive
vasculopathy
Circle of Willis assessment, Pres
aneurysm, stenosis of vessels
Biomarkers of CAA (Cerebral
amyloid angiopathy)
Amyloid deposition in vessels on
H&E staining and Congo red þ b
antibody staining
Biomarkers of atherosclerosis
or thrombotic disease
1. Presence of ischemia or hem
2. Presence of infarcts: number
location, acute or chronic, cyst
watershed, lacunar (white matt
matter, brain stem), laminar ne
hippocampal injury, cribriform
3. Incomplete ischemic injury
4. Loss of myelin on H&E and sp
such as LFB
Charnoly body (CB): A universal
pre-apoptotic biomarker of
compromised mitochondrial
bioenergetics and cell injury
Hippocampal lesions
Miscellaneous Mixed-multiple pathology
CVD Z cardiovascular disease; H&E Z hematoxylin and eosin; VaD ZFurthermore, the Hachinski ischemic score scale is a sim-
ple bedside clinical biomarker and currently used for
differentiating types of dementia (primary degenerative,
vascular, multi infarct, mixed type). A cut-off score  4 for
dementia of other types and  7 for VaD has a sensitivity of
89% and a specificity of 89%.84,85 The Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th Edition (DSM-IV)
Criteria for VaD take into account memory impairment, one
of the cognitive disturbances such as aphasia, apraxia,
agnosia and laboratory imaging findings in support of
vascular etiology.13 International Classification of Diseases-
10 Research Criteria (DCR-10) for VaD is similar to DSM IV
criteria with additional evaluation of consciousness, and
decline in emotional and social behavior. AD Diagnostic and
Treatment Centers Criteria for the Diagnosis of Probable
Ischemic VaD takes into consideration memory decline,
history of vascular risk factors, neurological signs, and
neuroimaging findings, relatively early appearance of gait
disturbance and urinary incontinence to favor diagnosis of
dementia with probable ischemic etiology. Ischemic scores
classified as VD by different diagnostic guidelines set by
Hachinski as follows: score indicating VaD  7; AD Diag-
nostic and Treatment Centers criteria: 10.3  3.4; DSM-IV
criteria: 6.5  4.4; DCR-10 criteria: 7.9  4.0; NINDS-
AIREN criteria: 12.5  2.6. Orthostatic circulatory distur-
bances such as alteration in mean arterial pressure,
postural hypotension have been shown to be associatedDiagnostic utility
Familial small vessel diseases
luminal
ica media,
Assesses microvascular angiopathy
Noncerebral amyloid angiopathy associated
angiopathy
ence of Marker for atherosclerosis
routine
amyloid
Indicator of CAA
orrhage
, size,
ic,
er, grey
crosis,
change.
ecial stain
Assesses cerebrovascular injury
Strong parameters of CVD and VaD, correlated
clinically and with imaging findings
CVD
Leukoencephalopathy.
Need to be validated and distinguished form
lesions in Alzheimer’s disease (CB as a
biomarker of compromised mitochondrial
bioenergetics)
CVD
vascular dementia.
54 A. Jagtap et al.with development of VaD and in some other neurodegen-
erative diseases.86e88Limitations in biomarker studies
Although biomarkers have been studied extensively, there
is no consensus on several issues such as definitions of
standard procedures, uniqueness of processing and stor-
age, analysis and interpretation of results and their
diagnostic utility. It is important to identify a biomarker
that is not only specific but also stable. In routine clinical
practice it is desirable to use the biomarkers with stability
due to constraints of time and handling of specimens e.g.
RNA stabilizers or exclusion of RNA chips, use of antico-
agulants may give rise to variable results. Large multi-
centric trials are necessary to compare diagnostic
accuracy of different laboratories all over the world.21
There are limitations in use of different analytical
methods. For instance, enzyme-linked immunosorbent
assay, used routinely may differ from Luminex’s xMAP
technology when CSF and plasma samples are analyzed,
which also affects the cut off values hence, standardiza-
tion of international standard values is required. Valida-
tion of biomarkers in body fluids need standardization
with universal and valid criteria for clinical diagnosis,
defining healthy controls, reproducibility in multiple
centers and correlated with standard postmortem diag-
nosis. CSF diagnosis of dementia supports only clinical and
not postmortem diagnosis. Novel potential biomarkers of
VaD such as asymmetrical dimethylarginine, which is a
biomarker of endothelial dysfunction, adhesion molecule
P-selectin may contribute to vascular processes and
thereby dementia need larger studies and validation.7
Currently CSF isoprostane, a biomarker of oxidative
stress, Ab oligomer, a synuclein, TDP-43, CSF DJ-1, TDP-
43 are being investigated in AD. As dementia is defined as
mixed etiology, there is a dire need to consider all these
biomarkers along with newer biomarkers of vascular injury
in determining causal relationship to VaD. Innovative
neuroimaging techniques such as diffusion tensor imaging,
MRS, functional MRI, amyloid-b PET imaging may provide
newer insights in the etiopathogenesis of VaD.89 Gadolin-
ium diethylene triamine penta-acetic acid also has shown
promise in detecting vascular pathology in dementia;
however, all these imaging biomarkers need further
evaluation through multicentric trials. Dysfunction of
autonomic regulation of cerebral blood flow is also asso-
ciated with VaD where imaging biomarkers may provide
diagnostic utility.7 There has not been any consensus on
criteria, definitions, or analysis of VaD in neuropatholog-
ical assessment. Although numerous gross and microscopic
changes have been identified as diagnostic of VaD, there is
a need of multidisciplinary team performing large multi-
center clinicopathological studies and harmonize the
diagnostic approach and validate the biomarkers under
investigation; e.g. abandonment of the term lacunae,
which is a source of confusion; reducing interobserver
variability.24 Genetics and molecular biology may show a
definitive avenue towards diagnosis and behavior of VaD;
genome-wide association studies have become technically
feasible but are still expensive.Conclusion
In this communication, we have reviewed the recent liter-
ature on the development of VaD biomarkers. A variety of
candidate biomarkers identified in CSF and blood by neu-
roimaging methods, neuropathological examination, and
genetic analysis have shown promise in their utility as
biomarker for etiological diagnosis and behavior of vascular
cognitive impairment and VaD however, lack of specificity,
lack of criteria to identify and define the components of
VaD prompts further large scale studies and evaluation of
these biomarkers and need to develop novel biomarkers.
The recent discovery of CB formation as a preapoptotic
biomarker of oxidative stress and compromised mitochon-
drial bioenergetics may serve as a novel biomarker of VaD.
In addition, biomarkers of oxidative and nitrative stress in
serum and CSF samples can be detected for the early
diagnosis, treatment and prognosis of VaD. A further study
in this direction will go a long way in the clinical manage-
ment of VaD.
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